about
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytomaGenome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathyHematologic β-tubulin VI isoform exhibits genetic variability that influences paclitaxel toxicity.Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomasGenetics of pheochromocytoma and paraganglioma in Spanish patients.Rationalization of genetic testing in patients with apparently sporadic pheochromocytoma/paraganglioma.Comparative analysis of Drosophila melanogaster and Caenorhabditis elegans gene expression experiments in the European Soyuz flights to the International Space Station.Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy.Deep sequencing reveals microRNAs predictive of antiangiogenic drug responseDifferential gene expression of medullary thyroid carcinoma reveals specific markers associated with genetic conditions.Genetic variation in the SLC19A1 gene and methotrexate toxicity in rheumatoid arthritis patients.Functional and in silico assessment of MAX variants of unknown significance.Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.SDHC mutation in an elderly patient without familial antecedents.Molecular characterisation of a common SDHB deletion in paraganglioma patients.Transposon mutagenesis identifies chromatin modifiers cooperating with Ras in thyroid tumorigenesis and detects ATXN7 as a cancer gene.Allelic variant at -79 (C>T) in CDKN1B (p27Kip1) confers an increased risk of thyroid cancer and alters mRNA levels.VEGF, VEGFR3, and PDGFRB protein expression is influenced by RAS mutations in medullary thyroid carcinoma.Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis.Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathwaysTumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosisSingle nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective studyThe miR-200 family controls -tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patientsWhole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathyHsa-miR-139-5p is a prognostic thyroid cancer marker involved in HNRNPF-mediated alternative splicing
P50
Q28241168-9C3955DD-FC54-4D85-9F36-304243EBEB55Q28943314-597A21C6-B71F-44AF-A937-DFD1A21923DBQ33402393-33C364AA-78AF-4D71-B192-1157B93679B8Q33637176-202C25D8-F713-4CFD-86B3-10788A0EA767Q34955974-A32C7568-82AA-41A5-A2B0-9D3CAEDC1E6EQ34974004-36096E57-ABD5-4F56-A97F-4DDB042CDD25Q36274477-77C3297F-693F-4DDF-A997-E83E544A8E04Q36877796-51189AE8-CC30-4AC7-B2C5-7C0B4CFA22F6Q37277227-75E0F82B-76A5-4119-A9E3-987A9BE05B40Q38493773-6D845D26-F9BF-43E1-91AA-CBBA16DF1077Q39245507-B4C1F1D1-483A-42C8-8FBE-F85742EA6881Q40840010-4346212A-4B4E-4D19-A1FC-7A2495BB0E59Q44247719-1CA0FF48-140A-4311-AAC1-3FB47C055109Q46444769-2F579A0E-89F2-447E-AE86-0A8AB081DD7CQ46868140-9525241C-C869-4424-801F-4CC00CC6DEDEQ52621195-75B88DED-16EF-471F-86B9-CFBEA81FD77CQ53348388-069A55D3-A317-4FA8-814D-DB233037B14EQ54358248-606DD7CE-87C0-4F84-8C99-24ABE2DEF03BQ54719085-69A95CA2-C2F7-4FFD-B4D5-C5696C5A3A47Q60895632-D4179BD5-E15E-448E-B988-159C481DFB64Q60895635-9F8CAC66-AAB3-4DAF-9BFE-4509CAA8CB51Q60895639-69E7B65C-A0BB-484E-BAE0-5FFD887552C4Q60895640-6447DE5E-AB64-45C5-AF92-83924D29247EQ64049797-9B61ECD4-65F8-4F01-AA49-19DD98CDD910Q92558531-5C066DA4-34F9-479F-8E42-9D189174A6C3
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Luis J Leandro-García
@ast
Luis J Leandro-García
@en
Luis J Leandro-García
@es
Luis J Leandro-García
@nl
type
label
Luis J Leandro-García
@ast
Luis J Leandro-García
@en
Luis J Leandro-García
@es
Luis J Leandro-García
@nl
altLabel
Luis Leandro-Garcia
@en
prefLabel
Luis J Leandro-García
@ast
Luis J Leandro-García
@en
Luis J Leandro-García
@es
Luis J Leandro-García
@nl
P1053
B-4229-2019
P106
P31
P496
0000-0002-7757-2408